The fact that biologic drugs are typically infused or injected poses numerous challenges, including discomfort for patients, instability under some storage conditions, and the generation of needle waste. Researchers have long sought a way to deliver biologics orally, and some teams have even reported progress toward the goal of delivering monoclonal antibodies in coated tablet forms. Now, researchers have reported in Nature Medicine that a luminal unfolding microneedle injector could be a feasible delivery device for biologic drugs like insulin.
The fact that biologic drugs are typically infused or injected poses numerous challenges, including discomfort for patients, instability under some storage conditions, and the generation of needle waste. Researchers have long sought a way to deliver biologics orally, and some teams have even reported progress toward the goal of delivering monoclonal antibodies in coated tablet forms. Now, researchers have reported in Nature Medicine that a luminal unfolding microneedle injector could be a feasible delivery device for delivering drugs like insulin.
The researchers, in a study funded by Novo Nordisk and the National Institutes of Health, developed a capsule that can carry insulin—and potentially other biologics—into the small intestine, where the capsule breaks down to reveal dissolvable microneedles on 3 folded arms. These needles attach to the intestinal wall and release the drug.
To allow the capsule to reach the small intestine, the researchers coated it with a polymer that can withstand stomach acidity until it reaches a pH of approximately 6.
Each of the arms, which are designed to break apart in order to reduce the risk of intestinal blockage, is covered with patches of 1 mm microneedles that are able to penetrate the topmost layer of the small intestine before they release the drug and dissolve.
In ex vivo human studies and in vivo swine studies, the capsule was demonstrated to load a comparable amount of insulin into test subjects as an injection would, allowing for fast uptake into the bloodstream; in the insulin tests, when the capsule was activated, the injector provided faster pharmacokinetic uptake than a subcutaneous injection over a 4-hour period.
In swine, no blockages formed in the intestine, and the capsule’s arms were safely excreted.
"We are really pleased with the latest results of the new oral delivery device our lab members have developed with our collaborators, and we look forward to hopefully seeing it help people with diabetes and others in the future," said Robert Langer, ScD, the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT) and a member of the Koch Institute for Integrative Cancer Research, in a statement.
Giovanni Traverso, PhD, assistant professor in MIT's Department of Mechanical Engineering and gastroenterologist at Brigham and Women's Hospital, added that "We can deliver insulin, but we see applications for many other therapeutics and possibly vaccines," Traverso says. "We're working very closely with our collaborators to identify the next steps and applications where we can have the greatest impact."
Reference
Abramson A, Caffarel-Salvador E, Soares V, et al. A luminal unfolding microneedle injector for oral delivery of macromolecules. Nat Med. 2019;25:1512-1518. doi: 10.1038/s41591-019-0598-9.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
EHA Poster Shows Transfusion Avoidance Rates Were Comparable Between Eculizumab Biosimilar, Soliris
Published: June 15th 2024 | Updated: June 14th 2024A poster from the European Hematology Association’s (EHA) 2024 annual meeting in Madrid, Spain, showed similar rates of transfusion avoidance between patients with paroxysmal nocturnal hemoglobinuria who were administered reference eculizumab (Soliris) and those administered an eculizumab biosimilar (SB12).
New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers
June 11th 2024Posters from the American Society of Clinical Oncology annual meeting showcased safety and efficacy data for a trastuzumab biosimilar and an ado-trastuzumab biosimilar in HER2-positive (HER2+) cancers.